Sofi-cel is an allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy being developed for T-cell cancers. Allotera uses ...

A mutation-agnostic CRISPR-Cas strategy that inserts a functional rhodopsin coding sequence into the human RHO locus has ...

Base editing offers far more versatility than its name implies. The technique was initially developed to correct ...

Researchers have identified how the bacteriophage protein AcrIIA27 inhibits diverse Cas9 enzymes by binding solvent-exposed regions of the guide RNA rather than the protein itself. This structural ...

On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based epigenetic silencer targeting chronic hepatitis B virus ...

The team behind Ariya Bio, from left to right: Mierelle Schuijt (Research Associate), Aniruddhan Balakrishnan (Corporate Strategy Intern), Mandy Boontanrart (Cofounder), Maike Getwan (Research Intern) ...

The company’s lead candidate, AXL-003, is advancing towards preclinical evaluation in an autoimmune indication with liver-targeted delivery. This programme builds directly on results showing that AXL ...

A mutation-agnostic CRISPR-Cas strategy that inserts a functional rhodopsin coding sequence into the... CRISPR Trials Global Overview Q2 2026 from CMN... Sep. 10, 2026 CMN Intelligence has released ...

Conventional CRISPR-CAS9 tools trigger immune responses in host animals, which can systematically distort screening results and mask genuine cancer vulnerabilities. A novel platform called StealTHY ...

Base editing offers far more versatility than its name implies. The technique was initially developed to correct single-nucleotide variants by... Dense RNA Modifications Boost Prime Editing in ...

Scientists engineered ultrasound-controlled CRISPR tools that can precisely edit genes deep within tissues, demonstrating successful gene regulation and cancer cell targeting in vitro and in vivo. In ...